Parexel has launched ParexelAI, a proprietary suite of human-led AI services and capabilities designed to improve speed, quality, and efficiency across the clinical development lifecycle for the life sciences industry.
The platform integrates AI with human oversight and transparency, covering processes from early-stage clinical trials through post-market surveillance.
ParexelAI is already delivering measurable operational gains, including a 50% reduction in site selection timelines, 30% faster clinical study report preparation, and a 20% reduction in safety literature screening and pharmacovigilance case processing.
Through its acquisition of Vitrana, Parexel now offers an integrated pharmacovigilance platform using intelligent automation and AI to improve compliance, quality, and patient safety workflows.
According to CEO Peyton Howell, “ParexelAI represents years of deep technology integration, all in service of helping our customers deliver life-changing treatments to patients.”
She added that the platform reflects the company’s broader growth strategy and commitment to helping sponsors conduct faster and more effective trials.
Chief Operating Officer Rob Goodwin said the tools automate repetitive manual tasks, enabling teams to focus on higher-value insights and operational excellence. Parexel is also collaborating with Paradigm Health to improve patient identification and trial access across more than 800 research sites and 2,100 provider locations.
Additionally, a partnership with Weave Bio is helping reduce Investigational New Drug (IND) and New Drug Application (NDA) authoring timelines by 60% using regulatory automation.
Parexel also became the first CRO to adopt Palantir Technologies’s AI platform for AI-enabled clinical operations.
Also Read: Parexel Teams with Weave Bio to Fast-Track Drug Regulatory Filing
Chief AI & Regulatory Strategy Officer Tala Fakhouri emphasized, “AI delivers its greatest value when it amplifies human expertise,” highlighting the company’s human-in-the-loop approach focused on quality, compliance, and patient safety.
The AI-powered clinical research sector is rapidly evolving as pharmaceutical companies push to reduce trial costs and speed up drug approvals. CROs and biotech firms are increasingly adopting generative AI, predictive analytics, and automation to improve patient recruitment, clinical documentation, and safety monitoring. Major healthcare technology firms are investing heavily in AI-driven pharmacovigilance and regulatory automation.
Partnerships between CROs, AI startups, and cloud providers are also expanding globally. Regulators are simultaneously developing frameworks to ensure ethical AI deployment in clinical trials. The sector’s focus is shifting toward “human-guided AI,” where automation supports experts instead of replacing clinical decision-making.
Parexel is a leading global Clinical Research Organization (CRO) that provides clinical development, consulting, regulatory, and market access services to the life sciences industry. Founded in 1982, the company supports pharmaceutical, biotechnology, and medical device firms in conducting clinical trials and bringing treatments to market faster. Parexel operates globally with more than 22,000 experts specializing in clinical operations, AI, regulatory strategy, and patient safety.
.jpg)
.jpg)
